Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 314, Issue 20, 2015, Pages 2137-2146

  Gross, Jeffrey G ^a   Glassman, Adam R ^b   Jampol, Lee M ^c   Inusah, Seidu ^b   Aiello, Lloyd Paul ^d   Antoszyk, Andrew N ^e   Baker, Carl W ^f   Berger, Brian B ^g   Bressler, Neil M ^h   Browning, David ^e   Elman, Michael J ⁱ   Ferris, Frederick L ^j   Friedman, Scott M ^k   Marcus, Dennis M ^l   Melia, Michele ^b   Stockdale, Cynthia R ^c   Sun, Jennifer K ^d   Beck, Roy W ^b  

^a Carolina Retina Center   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HARVARD UNIVERSITY   (United States)

^e Charlotte Eye   (United States)

^f Paducah Retinal Center   (United States)

^g Retina Research Center   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ Elman Retina Group   (United States)

^j NATIONAL EYE INSTITUTE   (United States)

^k Florida Retina Consultants   (United States)

^l Southeast Retina Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; PANRETINAL PHOTOCOAGULATION; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; RANDOMIZED CONTROLLED TRIAL; RETINA NEOVASCULARIZATION; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT; VITRECTOMY; ADVERSE EFFECTS; AREA UNDER THE CURVE; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; INTENTION TO TREAT ANALYSIS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; TIME; TREATMENT OUTCOME; UTILIZATION;

ADULT; ANGIOGENESIS INHIBITORS; AREA UNDER CURVE; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; INTRAVITREAL INJECTIONS; LIGHT COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 84948165075     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.15217     Document Type: Article

References (23)

1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-1239.
2. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005;353(8):839-841.
3. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: Centers for Disease Control and Prevention; 2007.
4. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88(7):583-600.
5. Silva PS, Cavallerano JD, Sun JK, et al. Proliferative diabetic retinopathy. In: Ryan SJ, ed. Retina. 5th ed. Philadelphia, PA: Elsevier; 2013.
6. Rezaei KA, Stone TW, eds. Global Trends in Retina Survey. Chicago, IL: American Society of Retina Specialists; 2014. https://www.asrs.org /content/documents/2014-global-trends -comprehensivepostmtg.pdf. Accessed February 18, 2015.
7. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: EARLY Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103(12):1796-1806.
8. Brucker AJ, Qin H, Antoszyk AN, et al; Diabetic Retinopathy Clinical Research Network. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol. 2009;127(2):132-140.
9. Googe J, Brucker AJ, Bressler NM, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009-1027.
10. Elman MJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077.e35.
11. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.
12. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152.
13. World Medical Association.World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
14. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194-205.
15. Aiello LP, Beck RW, Bressler NM, et al; Diabetic Retinopathy Clinical Research Network. Rationale for the Diabetic Retinopathy Clinical Research Network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118 (12):e5-e14.
16. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
17. Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114(10):1804-1809.
18. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199-200.
19. SAS Institute Inc. SAS/STAT 9.3 User's Guide. Cary, NC: SAS Institute Inc; 2011.
20. Diabetic Retinopathy Clinical Research Network. Reproducibility of spectral domain optical coherence tomography retinal thickness measurements and conversions to equivalent time domain metrics in diabetic macular edema. JAMA Ophthalmol. 2014;132(9):1113-1022.
21. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81-106.
22. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131(3):283-293.
23. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.